secwatch.observer — SEC 8-K summary
======================================

Issuer:     Allogene Therapeutics, Inc. (ALLO)
CIK:        0001737287
Form:       8-K
Filed at:   2024-06-10T23:59:59+00:00
Accession:  0001737287-24-000050
Event type: leadership
Sentiment:  neutral
Materiality: 0.25
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Allogene appoints new principal accounting officer; shareholders elect directors and ratify auditor
--------------------------------------------------------------------------------

- Annie Yoshiyama appointed principal accounting officer, replacing Geoffrey Parker; Parker remains CFO.
- Yoshiyama previously VP Finance & Controller at AN2 Therapeutics and CAO at Tricida.
- Shareholders elected four Class III directors (DeYoung, Humer, Kazam, Mayo) to serve until 2027.
- Advisory say-on-pay approved with 119.7M votes for, 16.3M against.
- Ernst & Young ratified as independent auditor for fiscal year ending December 31, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000050/0001737287-24-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1737287/000173728724000050/allo-20240605.htm
  HTML page:      https://secwatch.observer/filing/0001737287-24-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer